Omid Hamid, MD of The Angeles Clinic discusses immune related adverse events within melanoma and other disease states at Scripps…
Browsing: Acute Lymphoblastic Leukemia
At the German Cancer Congress 2016, held in Berlin, Germany from 24 February to 27 February 2016, Thomas Seufferlein, MD,…
Pancreatic cancer is a leading cause of cancer-related deaths in developed countries. At the German Cancer Congress 2016, held in…
At the German Cancer Congress 2016, held in Berlin, Germany from 24 February to 27 February 2016, Thomas Seufferlein, MD,…
Owen A O’Connor, MD, PhD from the Columbia University Medical Center Center for Lymphoid Malignancies, New York, NY, talks about…
Wyndham Wilson, MD, PhD from the National Cancer Institute, Bethesda, MD talks about the concept of precision medicine in lymphoid…
Wyndham Wilson, MD, PhD from the National Cancer Institute, Bethesda, MD talks about the new developments in the fields of…
Wyndham Wilson, MD, PhD from the National Cancer Institute, Bethesda, MD talks about drugs that have been developed to indirectly…
Owen A O’Connor, MD, PhD from the Columbia University Medical Center Center for Lymphoid Malignancies, New York, NY, talks about…
Owen A O’Connor, MD, PhD from the Columbia University Medical Center Center for Lymphoid Malignancies, New York, NY, discusses the…
Owen A O’Connor, MD, PhD from the Columbia University Medical Center Center for Lymphoid Malignancies, New York, NY, talks about…
Owen A O’Connor, MD, PhD from the Columbia University Medical Center Center for Lymphoid Malignancies, New York, NY, presents the…
Elias Jabbour, MD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about the different forms of…
Elias Jabbour, MD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about a Phase II clinical…
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR discusses some of the…
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR discusses the results of…
Anders Österborg, MD, PhD from the Karolinska Hospital & Institute, Stockholm in Sweden gives an overview of the data presented…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
Recent advances in the understanding of the biology of thyroid cancer have led to the development of targeted therapies, such…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
Morie A. Gertz, MD of Mayo Clinic discusses the indications for systemic therapy of Waldenstroms Macroglobulinemia at Scripps Health 36th…
Morie A. Gertz, MD of Mayo Clinic discusses the standard of care options for frontline therapy of Waldenstroms Macroglobulinemia at…
Morie A. Gertz, MD of Mayo Clinic discusses the roles of proteasome inhibitors and immunomodulatory agents in Waldenstroms Macroglobulinemia at…
Morie A. Gertz, MD of Mayo Clinic discusses Ibrutinib and Waldenstroms Macroglobulinemia at Scripps Health 36th Annual Conference: Clinical Hematology…
Morie A. Gertz, MD of Mayo Clinic discusses MYD88 mutation and management of Waldenstroms Macroglobulinemia at Scripps Health 36th Annual…
Morie A. Gertz, MD of Mayo Clinic discusses Panobinostat and other HDAC inhibitors in relapsed Multiple Myeloma at Scripps Health…
Morie A. Gertz, MD of Mayo Clinic discusses how Ixazomib will change therapeutic algorithms for myeloma at the Scripps Health…
Morie A. Gertz, MD of Mayo Clinic discusses elotuzumab second line or third line regimen following a Proteasome-IMiD based combination…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
Morie A. Gertz, MD of Mayo Clinic discusses how Daratumumab is to be used anti-CD38 monoclonal antibody Scripps Health 36th…
Morie A. Gertz, MD of Mayo Clinic discusses the new novel agents which might have significant therapeutic impact in multiple…
Ryan Cassaday, MD, from Fred Hutchinson Cancer Research Center, Seattle, WA, discusses clinical data presented on acute lymphoblastic leukemia (ALL)…
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about venetoclax (ABT-199), which…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Stephen Nimer, MD, from Memorial Sloan-Kettering Cancer Center,…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Stephen Nimer, MD, from Memorial Sloan-Kettering Cancer Center,…
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX discusses the side-effects profile of…
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about the importance of…
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about recent advances in…
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR talks about gene expression…
At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss several…
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR discusses the future of…
Véronique Leblond, MD, PhD from the Hospital of Pitié Salpêtrière, Paris, France, talks about one of the arms of the…
Hagop Kantarjian, MD of MD Anderson Cancer Center discusses how FLT3 occurs in about a third of adult AML patients…
Hagop Kantarjian, MD of MD Anderson Cancer Center discusses phase III RATIFY trial 7+3 chemo plus Midostaurin or placebo in…
Hagop Kantarjian, MD of MD Anderson Cancer Center discusses Quizartinib FLT3 inhibitor status at the Scripps 36th Annual Conference: Clinical…
Hagop Kantarjian, MD of MD Anderson Cancer Center discusses the fact that no data for FLT3 inhibitor more effective than…
Hagop Kantarjian, MD of MD Anderson Cancer Center discusses IDH1 and IDH2 results in AML at the Scripps 36th Annual…
Hagop Kantarjian, MD of MD Anderson Cancer Center discusses DNMT3A and the impact on the course of AML at the…
Hagop Kantarjian, MD of MD Anderson Cancer Center discusses the new targetable molecular abnormalities in AML at the Scripps 36th…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…